Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Graceway Pharmaceuticals, LLC |
---|---|
Information provided by: | Graceway Pharmaceuticals, LLC |
ClinicalTrials.gov Identifier: | NCT00116662 |
The primary purpose of this study is to evaluate the effectiveness in pediatric subjects of three different strengths of resiquimod gel applied to common wart(s) three times a week for up to twelve weeks.
A second purpose is to evaluate the safety of the drug.
Condition | Intervention | Phase |
---|---|---|
Warts |
Drug: Resiquimod |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Single Blind, Dose Comparison, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Single-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 3 Times Per Week for up to 12 Weeks for the Treatment of Common Warts in Pediatric Subjects |
Ages Eligible for Study: | 3 Years to 11 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Arkansas | |
Arkansas | |
Fayetteville, Arkansas, United States, 72703 | |
Arkansas | |
Little Rock, Arkansas, United States, 72205 | |
United States, Georgia | |
Georgia | |
Newnan, Georgia, United States, 30263 | |
United States, Illinois | |
Illinois | |
Buffalo Grove, Illinois, United States, 60089 | |
United States, Indiana | |
Indiana | |
Lafayette, Indiana, United States, 47904 | |
United States, Kansas | |
Kansas | |
Wichita, Kansas, United States, 67207 | |
United States, Massachusetts | |
Massachusetts | |
Boston, Massachusetts, United States, 02114 | |
United States, Missouri | |
Missouri | |
St. Louis, Missouri, United States, 63110 | |
United States, Utah | |
Utah | |
Layton, Utah, United States, 84041 | |
United States, Vermont | |
Vermont | |
Burlington, Vermont, United States, 05401 |
Study ID Numbers: | 1534-RESI |
Study First Received: | June 30, 2005 |
Last Updated: | February 16, 2007 |
ClinicalTrials.gov Identifier: | NCT00116662 |
Health Authority: | United States: Food and Drug Administration |
Wart(s) Common Wart(s) Children |
Pediatric 3M Pharmaceuticals Resiquimod |
Virus Diseases Skin Diseases, Infectious Warts |
Skin Diseases DNA Virus Infections Papillomavirus Infections |
Skin Diseases, Viral Neoplasms Tumor Virus Infections |